momelotinib sold brand name ojjaara anticancer medication used treatment janus kinase inhibitor taken common adverse reactions include dizziness fatigue bacterial infection hemorrhage thrombocytopenia diarrhea momelotinib approved medical use united states september momelotinib indicated treatment intermediate highrisk myelofibrosis adults inhibitor janus kinases acting atp competitor values nm respectively inhibitor significantly less active towards kinases including november committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product omjjara intended treatment diseaserelated splenomegaly symptoms adults moderatetosevere anemia primary myelofibrosis postpolycythaemia vera myelofibrosis postessential thrombocythaemia applicant medicinal product glaxosmithkline trading services antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikimomelotinib